Stock Market Reviews

BMRN (BioMarin Pharmaceutical Inc.) News

Get the latest news, insights, and market updates on BMRN (BioMarin Pharmaceutical Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab
  BioMarin Pharmaceutical (NASDAQ:BMRN) executives used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline the company’s refreshed strategy, discuss upcoming competitive dynamics for Voxzogo, and frame key growth and margin expectations tied to its core rare disease franchises
  Mar 7, 2026 - $BMRN
• Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus
  Shareholders of Amicus Therapeutics have approved the company's acquisition by BioMarin Pharmaceutical. The deal now moves to remaining regulatory reviews before the parties can close the transaction. The acquisition is expected to close following completion of these final approvals, subject to customary conditions. For holders of NasdaqGM:FOLD, this vote marks a clear inflection point for Amicus Therapeutics, which last closed at $14.33. The stock has returned 56.6% over the past year and...
  Mar 5, 2026 - $BMRN
• BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
  On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in adolescents aged 12 and older. FDA’s Expanded Approval The FDA approved BioMarin’s supplemental Biologics License Application for Palynziq, making it the only enzyme substitution therapy approved for PKU management in pediatric patients aged 12 and older. Phenylketonuria is a rare inherited disorder that c
  Mar 4, 2026 - $BMRN
• Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
  Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somara
  Mar 3, 2026 - $BMRN
• 2 Reasons to Like BMRN (and 1 Not So Much)
  BioMarin Pharmaceutical currently trades at $61.02 per share and has shown little upside over the past six months, posting a middling return of 3.5%.
  Mar 3, 2026 - $BMRN
• Ascendis wins FDA approval of dwarfism drug
  Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.
  Mar 2, 2026 - $BMRN
• A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound
  BioMarin Pharmaceutical (BMRN) has been drawing attention after recent share price moves, with the stock up about 9% over the past month and roughly 12% over the past 3 months. See our latest analysis for BioMarin Pharmaceutical. That recent 9% 30 day share price return and 12% 90 day share price return sit against a weaker backdrop, with the 1 year total shareholder return around 13% lower. This suggests that short term momentum has picked up even as longer term holders remain under...
  Mar 1, 2026 - $BMRN
• Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best cheap biotech stocks to buy now. Canaccord lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $104 from $98 on February 26 and reiterated a Buy rating on the shares. It stated that while the company’s fiscal Q4 2025 earnings showed a slight top-line beat, […]
  Mar 1, 2026 - $BMRN
• U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
  BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for PALYNZIQ® (pegvaliase-pqpz) to include pediatric patients 12 years of age and older with phenylketonuria (PKU). PALYNZIQ is the only enzyme substitution therapy approved to reduce blood phenylalanine (Phe) concentrations in people with PKU.
  Feb 28, 2026 - $BMRN
• Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here’s Why
  BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, Bernstein lifted the price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to $94 from $90 and maintained an Outperform rating on the shares. It noted that revenues of $875 million beat by 5%, while EPS […]
  Feb 28, 2026 - $BMRN